Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks : an exploratory study. / Deligianni, Christina; Pellesi, Lanfranco; Chaudhry, Basit Ali; Haulund Vollesen, Anne Luise; Snoer, Agneta Henriette; Hannibal, Jens; Jensen, Rigmor Højland; Ashina, Messoud.
I: Frontiers in Neurology, Bind 14, 1135246, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks
T2 - an exploratory study
AU - Deligianni, Christina
AU - Pellesi, Lanfranco
AU - Chaudhry, Basit Ali
AU - Haulund Vollesen, Anne Luise
AU - Snoer, Agneta Henriette
AU - Hannibal, Jens
AU - Jensen, Rigmor Højland
AU - Ashina, Messoud
N1 - Publisher Copyright: Copyright © 2023 Deligianni, Pellesi, Chaudhry, Haulund Vollesen, Snoer, Hannibal, Jensen and Ashina.
PY - 2023
Y1 - 2023
N2 - Background: Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether infusions of PACAP and VIP caused alterations in plasma levels of VIP and their potential contribution to induced cluster headache attacks. Methods: Participants received either PACAP or VIP infusion for 20 min on 2 separate days with an interval of at least 7 days in between. Blood collection was performed at T0, T20, T30, and T90. Plasma levels of VIP were measured using a validated radioimmunoassay method. Results: Blood samples were collected from participants with episodic cluster headache in the active phase (eCHA, n = 14), remission (eCHR, n = 15), and from participants with chronic cluster headache (cCH, n = 15). Baseline levels of VIP did not differ among the three groups (p = 0.1161). During PACAP infusion, mixed-effects analysis revealed a significant increase in plasma levels of VIP in eCHA (p = 0.0300) and eCHR (p = 0.0058) but not in cCH (p = 0.2930). We found no difference in the increase of plasma VIP levels between patients who developed PACAP38- or VIP-induced attacks. Conclusion: Cluster headache attacks induced by PACAP38 or VIP infusion are not associated with changes in plasma levels of VIP. Further studies are needed to investigate the role of VIP and the parasympathetic system in cluster headache. Clinical trial registration: The parent study is registered at ClinicalTrials.gov (NCT03814226).
AB - Background: Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether infusions of PACAP and VIP caused alterations in plasma levels of VIP and their potential contribution to induced cluster headache attacks. Methods: Participants received either PACAP or VIP infusion for 20 min on 2 separate days with an interval of at least 7 days in between. Blood collection was performed at T0, T20, T30, and T90. Plasma levels of VIP were measured using a validated radioimmunoassay method. Results: Blood samples were collected from participants with episodic cluster headache in the active phase (eCHA, n = 14), remission (eCHR, n = 15), and from participants with chronic cluster headache (cCH, n = 15). Baseline levels of VIP did not differ among the three groups (p = 0.1161). During PACAP infusion, mixed-effects analysis revealed a significant increase in plasma levels of VIP in eCHA (p = 0.0300) and eCHR (p = 0.0058) but not in cCH (p = 0.2930). We found no difference in the increase of plasma VIP levels between patients who developed PACAP38- or VIP-induced attacks. Conclusion: Cluster headache attacks induced by PACAP38 or VIP infusion are not associated with changes in plasma levels of VIP. Further studies are needed to investigate the role of VIP and the parasympathetic system in cluster headache. Clinical trial registration: The parent study is registered at ClinicalTrials.gov (NCT03814226).
KW - cluster headache
KW - headache
KW - migraine
KW - PACAP38
KW - pain
KW - parasympathetic system
KW - VIP
UR - http://www.scopus.com/inward/record.url?scp=85159909681&partnerID=8YFLogxK
U2 - 10.3389/fneur.2023.1135246
DO - 10.3389/fneur.2023.1135246
M3 - Journal article
C2 - 37143998
AN - SCOPUS:85159909681
VL - 14
JO - Frontiers in Neurology
JF - Frontiers in Neurology
SN - 1664-2295
M1 - 1135246
ER -
ID: 364549098